Brief: TetraLogic Pharmaceuticals says birinapant shows no activity in randomized phase 2 mds study
06/01/2016 21:12
Jan 6 (Reuters) - TetraLogic Pharmaceuticals Corp TLOG.O : * Says birinapant shows no activity in randomized Phase 2 MDS study * Says shape shows clinical benefit in randomized phase 2 CTCL study * Placebo controlled Phase 2 study of birinapant study will now be terminated * In phase 2 study of birinapant co-administered with azacitidine birinapant did not demonstrate benefit over placebo * Final results from phase 2 clinical study of shape will be available in mid-2016 * Source text for Eikon urn:newsml:reuters.com:*:nGNXMJAYEa * Further company coverage TLOG.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Tetralogic Pharmaceuticals
See all newsNewscasts - Grieving father buries son killed by toxic cough syrup in India
Cellect: Soars on merger deal with Quoin Pharmaceuticals
Brief: Tetralogic announces pacts to restructure convertible debt
Brief: Tetralogic Pharmaceuticals says Pete Meyers resigned as CFO
Brief: TetraLogic Pharmaceuticals says birinapant shows no activity in randomized phase 2 mds study